Raleigh Capital Management Inc. Sells 11,248 Shares of Labcorp Holdings Inc. $LH

Key Points

• Raleigh Capital Management cut its Labcorp stake by 98.7% in Q4, selling 11,248 shares and leaving just 145 shares valued at about $36,000.
• Company insiders sold a total of 16,113 shares worth roughly $4.55 million last quarter (including EVP Jonathan Meltzer and Sandra van Der Vaart); insiders now own 0.84% of the stock while institutional investors hold about 95.94%.
• Labcorp beat Q4 EPS expectations ($4.07 vs. $3.95) but missed revenue estimates, set FY2026 guidance of 17.55–18.25 EPS, and carries a consensus analyst stance of "Moderate Buy" with an average price target of $307.70.

Raleigh Capital Management Inc. cut its holdings in Labcorp Holdings Inc. (NYSE:LH - Free Report) by 98.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 145 shares of the medical research company's stock after selling 11,248 shares during the period. Raleigh Capital Management Inc.'s holdings in Labcorp were worth $36,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Caldwell Trust Co bought a new position in Labcorp during the 2nd quarter valued at about $25,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in Labcorp during the 4th quarter valued at about $26,000. JPL Wealth Management LLC bought a new position in Labcorp during the 3rd quarter valued at about $28,000. Motco bought a new position in Labcorp during the 3rd quarter valued at about $32,000. Finally, Beacon Financial Strategies CORP bought a new position in Labcorp during the 4th quarter valued at about $33,000. 95.94% of the stock is currently owned by institutional investors.

Insider Activity at Labcorp

In other Labcorp news, EVP Jonathan C. Meltzer sold 87 shares of the business's stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $290.42, for a total value of $25,266.54. Following the completion of the sale, the executive vice president directly owned 2,782 shares of the company's stock, valued at $807,948.44. The trade was a 3.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Der Vaart Sandra D. Van sold 548 shares of the company's stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $284.91, for a total transaction of $156,130.68. Following the completion of the sale, the executive vice president directly owned 2,579 shares of the company's stock, valued at $734,782.89. The trade was a 17.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 16,113 shares of company stock valued at $4,547,450 in the last quarter. Corporate insiders own 0.84% of the company's stock.

Wall Street Analyst Weigh In

LH has been the topic of several analyst reports. Wall Street Zen downgraded shares of Labcorp from a "buy" rating to a "hold" rating in a report on Saturday. Piper Sandler upped their price target on shares of Labcorp from $270.00 to $300.00 and gave the company a "neutral" rating in a report on Tuesday, February 24th. Morgan Stanley reiterated an "overweight" rating on shares of Labcorp in a report on Tuesday, February 17th. Weiss Ratings upgraded shares of Labcorp from a "hold (c+)" rating to a "buy (b-)" rating in a report on Tuesday, February 10th. Finally, Robert W. Baird upped their price target on shares of Labcorp from $313.00 to $326.00 and gave the company an "outperform" rating in a report on Wednesday, February 18th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $307.70.

Labcorp Price Performance

Labcorp stock opened at $269.18 on Wednesday. The stock has a market cap of $22.18 billion, a price-to-earnings ratio of 25.73, a price-to-earnings-growth ratio of 1.87 and a beta of 1.02. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.42 and a quick ratio of 1.23. Labcorp Holdings Inc. has a 1 year low of $209.38 and a 1 year high of $293.72. The firm has a 50-day moving average of $274.38 and a two-hundred day moving average of $268.85.

Labcorp (NYSE:LH - Get Free Report) last released its quarterly earnings data on Tuesday, February 17th. The medical research company reported $4.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.95 by $0.12. The company had revenue of $3.52 billion during the quarter, compared to analysts' expectations of $3.56 billion. Labcorp had a net margin of 6.28% and a return on equity of 16.16%. The firm's quarterly revenue was up 5.6% on a year-over-year basis. During the same period in the previous year, the company earned $3.45 EPS. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. On average, research analysts forecast that Labcorp Holdings Inc. will post 16.01 earnings per share for the current year.

Labcorp Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 12th. Shareholders of record on Friday, February 27th were given a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend was Friday, February 27th. Labcorp's payout ratio is 27.53%.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp NYSE: LH, is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.